A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Fourth quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $57.3 million ---- March 20, 2026 PDUFA goal date ...

Artisan Global Discovery Fund achieved strong absolute returns in 2025 but trailed its index. Read the full analysis for more details.

Expanded into AI-resilient growth channels through enhanced mobile in-app capabilities and the release of Nexxen’s industry-first programmatic Smart TV home screen ad activation solution, which is now ...

GoodRx projects Pharma Direct revenue to grow at least 30% year-over-year in 2026. Management anticipates continued acceleration in condition-specific subscriptions launched in late 2025, with weight ...

RIVKIN Aesthetics reports the rise of weight loss drugs like GLP-1 is reshaping aesthetics, with many new patients seeking facial treatments.

LIMERICK, Ireland, Feb. 25, 2026 (GLOBE NEWSWIRE) -- kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF) ("Kneat" or the "Company") a leader in digitizing and automating validation and quality processes, today ...

The Bangladesh Bureau of Statistics (BBS) is conducting the country’s first Labour Demand Survey 2025 to generate demand-side labour data and guide employment, training and skills development policies ...

The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far ...

Virginia attracted $12 billion in pharmaceutical manufacturing investments in 2025, leveraging site readiness, workforce training, and strong infrastructure.

Outlining four developments set to change how life-sciences organizations design, deploy, and govern intelligent systems in the year ahead.

Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. | The primary growth drivers in Bayer’s pharma sector—Nubeqa and ...